Bortezomib-induced neuropathy: Axonal membrane depolarization precedes development of neuropathy

Clinical Neurophysiology

Volumn 125, Issue 2, 2014, Pages 381-387

  Nasu, Saiko ^a   Misawa, Sonoko ^a   Nakaseko, Chiaki ^b   Shibuya, Kazumoto ^a   Isose, Sagiri ^a   Sekiguchi, Yukari ^a   Mitsuma, Satsuki ^a   Ohmori, Shigeki ^a   Iwai, Yuta ^a   Beppu, Minako ^a   Shimizu, Naomi ^b   Ohwada, Chikako ^b   Takeda, Yusuke ^b   Fujimaki, Yumi ^a   Kuwabara, Satoshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bortezomib; Membrane depolarization; Proteasome inhibitor; Threshold tracking

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BORTEZOMIB; DEXAMETHASONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEASUREMENT; MEDIAN NERVE; MEMBRANE DEPOLARIZATION; MEMBRANE STEADY POTENTIAL; MIDDLE AGED; MULTIPLE MYELOMA; NERVE CONDUCTION; NERVE CONDUCTION DISORDER; NERVE EXCITABILITY; NERVE FIBER DEGENERATION; NERVE FIBER MEMBRANE; NEUROPATHY; NEUROPHYSIOLOGICAL MONITORING; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

BORTEZOMIB; MEMBRANE DEPOLARIZATION; PROTEASOME INHIBITOR; THRESHOLD TRACKING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AXONS; BORONIC ACIDS; FEMALE; HUMANS; MALE; MEMBRANE POTENTIALS; MIDDLE AGED; MULTIPLE MYELOMA; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; PYRAZINES; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84892476107     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2013.07.014     Document Type: Article

References (37)

1. Argyriou A.A., Iconomou G., Kalofonos H.P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008, 112:1593-1599.
2. Argyriou A.A., Bruna J., Marmiroli P., Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012, 82:51-77.
3. Arnulf B., Pylypenko H., Grosicki S., Karamanesht I., Leleu X., van de Velde H., et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012, 97:1925-1928.
4. Badros A., Goloubeva O., Dalal J.S., Can I., Thompson J., Rapoport A.P., et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007, 110:1042-1049.
5. Bostock H., Rothwell J.C. Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol 1997, 498:277-294.
6. Bostock H., Cikurel K., Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998, 21:137-158.
7. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
8. Bringhen S., Larocca A., Rossi D., Cavalli M., Genuardi M., Ria R., et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010, 116:4745-4753.
9. Bruna J., Udina E., Alé A., Vilches J.J., Vynckier A., Monbaliu J., et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 2010, 223:599-608.
10. Cata J.P., Weng H.R., Burton A.W., Villareal H., Giralt S., Dougherty P.M. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007, 8:296-306.
11. Cavaletti G., Gilardini A., Canta A., Rigamonti L., Rodriguez-Menendez V., Ceresa C., et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007, 204:317-325.
12. Chaudhry V., Cornblath D.R., Polydefkis M., Ferguson A., Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008, 13:275-282.
13. Chen C.I., Kouroukis C.T., White D., Voralia M., Stadtmauer E., Stewart A.K., et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1570-1575.
14. Ciechanover A., Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003, 40:427-446.
15. Han S.E., Boland R.A., Krishnan A.V., Vucic S., Lin C.S., Kiernan M.C. Changes in human sensory axonal excitability induced by an ischaemic insult. Clin Neurophysiol 2008, 119:2054-2063.
16. Harousseau J.L., Attal M., Avet-Loiseau H., Marit G., Caillot D., Mohty M., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010, 28:4621-4629.
17. Kanai K., Kuwabara S., Misawa S., Tamura N., Ogawara K., Nakata M., et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain 2006, 129:953-962.
18. Kanai K., Shibuya K., Sato Y., Misawa S., Nasu S., Sekiguchi Y., et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012, 83:734-738.
19. Kiernan M.C., Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000, 123:2542-2551.
20. Kiernan M.C., Burke D., Andersen K.V., Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000, 23:399-409.
21. Kiernan M.C., Walters R.J., Andersen K.V., Taube D., Murray N.M., Bostock H. Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain 2002, 125:1366-1378.
22. Kyle R.A., Rajkumar S.V. Multiple Myeloma. N Engl J Med 2004, 351:1860-1873.
23. 2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005, 65:3828-3836.
24. Lin C.S., Kuwabara S., Cappelen-Smith C., Burke D. Responses of human sensory and motor axons to the release of ischaemia and to hyperpolarizing currents. J Physiol 2002, 541:1025-1039.
25. Lo A.C., Saab C.Y., Black J.A., Waxman S.G. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 2003, 90:3566-3571.
26. Meregalli C., Canta A., Carozzi V.A., Chiorazzi A., Oggioni N., Gilardini A., et al. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 2010, 14:343-350.
27. Moreau P., Pylypenko H., Grosicki S., Karamanesht I., Leleu X., Grishunina M., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.
28. Nodera H., Spieker A., Sung M., Rutkove S. Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy. Neurosci Lett 2011, 505:223-227.
29. Park S.B., Lin C.S., Krishnan A.V., Goldstein D., Friedlander M.L., Kiernan M.C. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009, 132:2712-2723.
30. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004, 10:3839-3852.
31. Ravaglia S., Corso A., Piccolo G., Lozza A., Alfonsi E., Mangiacavalli S., et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008, 119:2507-2512.
32. Richardson P.G., Briemberg H., Jagannath S., Wen P.Y., Barlogie B., Berenson J., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
33. Stys P.K., Ransom B.R., Waxman S.G. Tertiary and quaternary local anesthetics protect CNS white matter from anoxic injury at concentrations that do not block excitability. J Neurophysiol 1992, 67:236-240.
34. Stys P.K., Waxman S.G., Ransom B.R. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na channels and Na-Ca2 exchanger. J Neurosci 1992, 12:430-439.
35. Voorhees P.M., Dees E.C., O'Neil B., Orlowski R.Z. The proteasome as a target for cancer therapy. Clin Cancer Res 2003, 9:6316-6325.
36. Waxman S.G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat Clin Pract Neurol 2008, 4:159-169.
37. Zheng H., Xiao W.H., Bennett G.J. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol 2012, 238:225-234.